IFNB1 and COVID-19: Since our preliminary results were made public on June 29, 2020, WHO has halted the lopinavir–ritonavir monotherapy and the lopinavir–ritonavir plus interferon beta combination groups of the SOLIDARITY trial because the interim results are in line with those presented here—lopinavir–ritonavir does not improve clinical outcomes for patients admitted to hospital with COVID-19.30